dr reddy's glp-1 drugs portfolio 2025 Lilly's GLP-1 portfolio gains ground on Novo Nordisk Dr. Reddys Laboratories DMF, CEP,

GLP-1 receptor agonists, liraglutide and lixisenatide, also display neuroprotective properties in MPTP mouse models

And does it work better for weight loss than Ozempic and Wegovy

GLP-1 medications like semaglutide have transformed weight management for millions, yet they are not appropriate for everyone

There is much debate surrounding the tolerability of an increased risk of DKA, with comparisons being made with troglitazone and its subsequent removal from the market where the risk of fatal liver failure was greater than the current risk of DKA with SGLT2i use [31]

Get support If you need support with your weight loss journey, you can get help from WeightWatchers

Resistin is a key mediator of glucosedependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes